多索茶碱联合噻托溴铵粉雾剂治疗慢性 阻塞性肺疾病稳定期临床疗效

Clinical Effect of Doxofylline Combined with Tiotropium Bromide Powder in the Treatment of COPD at Stable Stage

摘要:

〔摘 要〕 目的：探讨多索茶碱联合噻托溴铵粉雾剂治疗慢性阻塞性肺疾病（COPD）稳定期患者的可行性。 方法：选取 2019 年 2 月至 2020 年 3 月期间于开封一五五医院治疗的 110 例 COPD 稳定期患者，根据随机数字表法 将其分为对照组与观察组，每组各 55 例。对照组患者采用多索茶碱治疗，观察组患者采用多索茶碱联合噻托溴铵粉 雾剂治疗，两组均连续治疗 2 周。于治疗 2 周后，比较两组患者临床疗效、动脉血氧分压（PaO2）、动脉血氧饱和度 （SaO2）、不良反应情况。 结果：观察组患者总有效率为 89.09 %，高于对照组患者的 58.18 %，差异具有统计学意义 （P ＜ 0.05）；治疗后，两组患者 PaO2、SaO2 水平均较治疗前升高，且观察组 PaO2、SaO2 水平均高于对照组，差异 具有统计学意义（P ＜ 0.05）；两组患者的不良反应总发生率比较，差异无统计学意义（P ＞ 0.05）。 结论：多索茶 碱联合噻托溴铵粉雾剂治疗 COPD 稳定期患者，能明显改善血气分析指标，且安全性高。

Abstract:

〔Abstract〕 Objective To investigate the feasibility of doxofylline combined with Tiotropium bromide aerosol in the treatment of chronic obstructive pulmonary disease (COPD). Methods A total of 110 patients with stable COPD treated in the 155th Hospital of Kaifeng from February 2019 to March 2020 were selected and divided into a control group and an observation group according to random number table method, with 55 cases in each group. The control group was treated with doxofylline, and the observation group was treated with doxofylline combined with Tiotropium bromide powder. Both groups were treated continuously for 2 weeks. After 2 weeks of treatment, clinical efficacy, arterial oxygen partial pressure (PaO2), arterial oxygen saturation (SaO2) and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 89.09 %, higher than 58.18 % of the control group, and the difference was statistically significant (P < 0.05). After treatment, PaO2 and SaO2 levels in the two groups were higher than before treatment, and PaO2 and SaO2 levels in the observation group were higher than those in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P > 0.05). Conclusion Doxofylline combined with tiotropium bromide powder aerosol in the treatment of stable COPD patients can significantly improve blood gas analysis indexes, and has high safety.